ClinicalTrials.gg
Enrolling by invitationNCT07625670REMINSITUUpdated Oct 20, 2026

Clinical Study to Evaluate Remineralization Using an in Situ Model.

A Phase 3 interventional study of Fluoride toothpaste containing 750 ppm MFP in a Dical base and Fluoride toothpaste containing 1450 ppm MFP in a Dical base in Remineralization, Enamel Lesions and Enamel Subsurface Lesion, sponsored by Colgate Palmolive. Enrolling by invitation at 1 site in Brazil. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Colgate Palmolive · Phase 3, Interventional, and Other

Updated Oct 20, 2026Now Enrolling by invitationStart date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a phase III clinical trial that aims to evaluate the enamel remineralization efficacy of three dentifrices on artificial caries lesions using an in situ model. The study involves 30 healthy volunteers, aged 18 to 70, who will participate in a randomized, triple-blind, three-period crossover design. Researchers will compare a 750 ppm MFP dentifrice against a 1450 ppm MFP positive control and a fluoride-free negative control to measure variations in mineral gain. Participants will wear a removable intraoral appliance containing human enamel blocks for three 14-day experimental phases. A 7-day washout period using will be implemented before and between each treatment phase.

Read the detailed description

This Phase III, randomized, single-center, triple-blind, crossover clinical study will evaluate the remineralization efficacy of three dentifrices on artificially induced initial enamel caries lesions. The research will involve 30 healthy participants aged 18 to 70 years who meet strict inclusion criteria. The experimental design will utilize an in situ model where participants will wear custom-made removable mandibular intraoral appliances containing four human enamel blocks with pre-formed artificial caries lesions. These lesions will be created laboratory-side using an acidified gel demineralization system before the blocks are mounted into the appliances.

The study will follow a nine-week timeline, divided into three 14-day experimental phases separated by 7-day washout periods to eliminate carryover effects, totaling 8 visits. During the treatment phases, subjects will be randomly assigned to a sequence of three test products: a test dentifrice with 750 ppm MFP, a positive control with 1450 ppm MFP, and a fluoride-free negative control. Each participant will receive a soft-bristle toothbrush and the assigned toothpastes.

The primary outcome will be the change in integrated mineral loss measured by transverse microradiography (TMR). Baseline mineral loss will be established from a slice of each block before intraoral exposure and compared to post-treatment analysis of the adjacent tissue. Secondary outcomes will include changes in lesion depth and fluorescence loss parameters assessed via Quantitative Light-induced Fluorescence (QLF).

Statistical analysis will be performed using a linear mixed-effects ANCOVA model to confirm the hypothesis that the 750 ppm MFP dentifrice promotes significantly greater remineralization than the negative control, with effects lower than or comparable to the high-fluoride positive control.

02

Conditions studied

  • Remineralization
  • Enamel Lesions
  • Enamel Subsurface Lesion

Keywords

  • enamel remineralization
  • transverse micro-radiography
03

In context

Lead sponsor

Colgate Palmolive is the lead sponsor of 120 studies on the registry; 14 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 2 (6%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females, between 18-70 years of age (inclusive);
  • Form signed and availability for the duration of the study;
  • Good general health (absence of any condition that, in the opinion of the Principal Investigator, might constitute a risk to the subject while participating in the study. Examples include heart problems, valve/hip replacements, etc);
  • Willingness to provide information related to their medical history;
  • Minimum of 20 uncrowned permanent natural teeth (excluding third molars);
  • Normal salivary flow;
  • Willingness to wear an intra-oral appliance all day as instructed except when eating and drinking.

Exclusion criteria

Exclusion Criteria:

  • Oral pathology, chronic disease, or a history of allergy to testing products;
  • Subject using anticonvulsants, antihistamines, antidepressants, sedatives, tranquilizers, anti-inflammatory medication or daily analgesics within one month prior to the start of the study or scheduled to start such intake during the course of the study;
  • Subject participating in any other clinical study;
  • Subject pregnant or breastfeeding;
  • Subject allergic to oral care products, personal care consumer products, or their ingredients;
  • Extended use of antibiotics or therapeutic mouthwash any time during the three months prior to entry into the study;
  • A medical history reporting that the subject has a current systemic or disease, such as diabetes, lupus, etc.;
  • Ongoing use of medications known to affect the gingival tissues (i.e. calcium channel blockers, phenytoin, cyclosporine);
  • Advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone). Pocket depth equal or greater than 4 mm;
  • Five or more decayed, untreated dental sites (cavities);
  • Current smokers and subjects with a history of alcohol or drug abuse;
  • Dental work prevents wearing of the appliance or a reported need to wear a night guard.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Test Group

    Subjects will brush using a fluoride toothpaste containing 750 ppm MFP in a Dical base and a soft bristle toothbrush

    Drug: Fluoride toothpaste containing 750 ppm MFP in a Dical base · Device: Toothbrush

  • Active comparator
    Positive Control Group

    Subjects will brush using a fluoride toothpaste containing 1450 ppm MFP in a Dical base and a soft bristle toothbrush

    Drug: Fluoride toothpaste containing 1450 ppm MFP in a Dical base · Device: Toothbrush

  • Sham comparator
    Negative Control Group

    Subjects will brush using a fluoride-free toothpaste in a Dical base and a soft bristle toothbrush

    Drug: Fluoride-free toothpaste in a Dical base · Device: Toothbrush

Interventions

  • DrugFluoride toothpaste containing 750 ppm MFP in a Dical base

    Subjects will brush using a fluoride toothpaste containing 750 ppm MFP in a Dical base and a soft bristle toothbrush for 14 days

  • DrugFluoride toothpaste containing 1450 ppm MFP in a Dical base

    Subjects will brush using a fluoride toothpaste containing 1450 ppm MFP in a Dical base and a soft bristle toothbrush for 14 days

  • DrugFluoride-free toothpaste in a Dical base

    Subjects will brush using a fluoride-free toothpaste in a Dical base and a soft bristle toothbrush for 14 days

  • DeviceToothbrush

    A commercially available adult soft bristle toothbrush

06

What researchers measure

Primary outcomes

  1. Change in integrated mineral loss (Δz)

    Integrated mineral loss (Δz) will be assessed by transverse microradiography (TMR). This outcome will evaluate the change from the baseline demineralized state (Δz0) to the post-treatment state (Δz1) to quantify the net mineral gain or loss.

    Time frame: 9 weeks

Secondary outcomes

  1. Change in lesion depth

    Post-treatments lesion depth (LD) will be assessed by TMR. For each experimental phase, post-treatment values will be compared with corresponding baseline measurements to determine the extent of remineralization.

    Time frame: 9 weeks

  2. Change from Baseline in Fluorescence Loss

    Fluorescence loss ΔF, will be assessed by quantitative light-induced fluorescence (QLF) to measure the percentage loss of fluorescence intensity. The change will be calculated by comparing post-treatment values at 9 weeks with baseline measurements.

    Time frame: 9 weeks

  3. Change from Baseline in Maximum Fluorescence Loss ΔFmax at 9 Weeks

    Maximum fluorescence loss ΔFmax at the deepest point of the lesion will be assessed by quantitative light-induced fluorescence (QLF). The change will be calculated by comparing post-treatment values at 9 weeks with baseline measurements.

    Time frame: 9 weeks

  4. Change from Baseline in Fluorescence Loss Volume (ΔQ) at 9 Weeks

    Fluorescence loss volume (ΔQ) will be assessed by quantitative light-induced fluorescence (QLF). The change will be calculated by comparing post-treatment values at 9 weeks with baseline measurements.

    Time frame: 9 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for Oct 2026, 1 month after the start.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Sep 2026, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2026
First posted
Jun 4, 2026
StartActual
Sep 3, 2026was Jun 2026
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Oct 20, 2026
Start date
Jun 2026→Sep 3, 2026 (actual)
Oct 20, 2026
Contact
No study contact listed any more: removed f•••@academico.ufpb.br · •••1111
Oct 20, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Federal University of Paraíba · João Pessoa, BrazilContact removed f•••@academico.ufpb.br · •••1111
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Not yet recruiting→Enrolling by invitation
    Start date Jun 2026→Sep 3, 2026 (now actual)
    Contact No study contact listed any more: removed f•••@academico.ufpb.br · •••1111
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Federal University of Paraíba · João Pessoa, BrazilContact removed f•••@academico.ufpb.br · •••1111
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07625670
Lead sponsor
Colgate Palmolive
Collaborators
Federal University of Paraíba
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Sep 3, 2026
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Oct 20, 2026

Study contacts

Fábio Correia Sampaio, PhD
principal investigator · Federal University of Paraíba

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion